Loading, Please Wait...
SAN DIEGO, Aug. 28, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today provided a progress report and marketing update on the U.S. launch of SYMJEPITM (epinephrine) 0.3 mg and 0.15 mg Injections.
During this back-to-school season, there is a heightened awareness of the shortage for epinephrine auto injectors. Adamis, in collaboration with Sandoz, Inc., hopes to alleviate some of the demand with their recently launched both doses of SYMJEPI into the hospital and retail market. Due to their efforts to broaden access for patients, nearly 90% of commercially insured people in the U.S. now have access to SYMJEPI through National and Regional Payers.
To ensure access for U.S. military personnel, retirees, and their dependents, SYMJEPI has been added to the Department of Defense’s (“DOD”) Uniform Formulary for Tricare, now effective as of early August. Public records indicate the DOD’s budget for epinephrine in fiscal 2016 was more than $57 million.
SYMJEPI was featured in an online USA Today article on August 14 in USA Today, “How to protect your children from life-threatening allergies.” Other marketing efforts underway include public relations programs, product donations to underserved US patients, patient advocacy efforts, personal selling, and raising awareness through scientific and consumer journal advertising. For a more detailed list of recent SYMJEPI press and scientific articles, please visit Adamis’ website here.
Dr. Dennis J. Carlo, President and Chief Executive Officer of Adamis Pharmaceuticals, stated, “We are excited to see the progress being made regarding the retail launch of SYMJEPI. Through our collaboration, we are increasing marketing efforts through several channels and these formulary additions should provide a broad foundation for growth of this product during a time of shortages of other products in this space. We look forward to seeing continued momentum through the end of the year and beyond.”
About Adamis Pharmaceuticals
Adamis Pharmaceuticals Corporation is a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including respiratory disease, allergy and opioid overdose. The company’s SYMJEPI (epinephrine) Injection 0.3mg and SYMJEPI (epinephrine) Injection 0.15mg products were approved by the FDA for use in the emergency treatment of acute allergic reactions, including anaphylaxis, and both were fully launched in the U.S. in July 2019. Please refer to www.SYMJEPI.com for additional product information. Adamis is developing additional products, including a naloxone injection product candidate, ZIMHI, for the treatment of opioid overdose, and a metered dose inhaler and dry powder inhaler product candidates for the treatment of asthma and COPD. The company’s subsidiary, U.S. Compounding, Inc., compounds sterile prescription drugs, and certain nonsterile drugs for patients, animals, hospitals, clinics and surgery centers throughout most of the United States.
Important Safety Information
WARNINGS AND PRECAUTIONS
Symjepi may cause serious side effects.
Common side effects of SYMJEPI include:
These side effects may go away with rest. Tell your healthcare provider if you have any side effect that bothers you or that does not go away.
These are not all the possible side effects of SYMJEPI. For more information, ask your healthcare provider or pharmacist.
For full prescribing and safety information, please click on this link.
You are encouraged to report negative side effects of prescription drugs to FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
Adamis Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future results of operations, including, but not limited to the following statements: the company’s beliefs concerning the commercial success of its SYMJEPI products; the company’s beliefs concerning the marketing and commercialization efforts of Sandoz relating to the SYMJEPI products; the company’s ability to provide an adequate supply of product; the company’s beliefs concerning the resources and capabilities that are required to provide access to its SYMJEPI product; the company’s ability to commercialize its product and product candidates, itself or through commercialization partners; the company’s beliefs concerning the ability of its products and product candidates to compete successfully in the market; the company’s beliefs concerning the safety and effectiveness of its products and product candidates; guidance regarding future periods; and other statements concerning our future operations and activities. Such forward-looking statements include those that express plans, anticipation, intent, contingencies, goals, targets or future development and/or otherwise are not statements of historical fact. These statements are only predictions, are not guarantees, involve known and unknown risks, uncertainties and other factors, and concern matters that could subsequently differ materially from those described in this press release, which may cause Adamis' actual results to be materially different from those contemplated by these forward-looking statements. There can be no assurances regarding the future commercial success of SYMJEPI. In addition, forward-looking statements concerning our anticipated future activities assume that we are able to obtain sufficient funding to support such activities and continue our operations and planned activities. As discussed in our filings with the Securities and Exchange Commission, we may require additional funding, and there are no assurances that such funding will be available if required. We cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. You should not place undue reliance on any forward-looking statements. Further, any forward-looking statement speaks only as of the date on which it is made, and except as may be required by applicable law, we undertake no obligation to update or release publicly the results of any revisions to these forward-looking statements or to reflect events or circumstances arising after the date of this press release. Certain of these risks, and additional risks, uncertainties, and other factors are described in greater detail in Adamis’ filings from time to time with the SEC, including its annual report on Form 10-K for the year ended December 31, 2018, and our subsequent filings with the SEC, which Adamis strongly urges you to read and consider, all of which are available free of charge on the SEC's web site at http://www.sec.gov.
Senior Director, Investor Relations
& Corporate Communications
Adamis Pharmaceuticals Corporation